YU2000A - Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens - Google Patents
Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agensInfo
- Publication number
- YU2000A YU2000A YU2000A YU2000A YU2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- atorvastatin
- combinations
- combination therapy
- antihypertensive agent
- hyperlipidemia
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 3
- 229940030600 antihypertensive agent Drugs 0.000 title abstract 3
- 239000002220 antihypertensive agent Substances 0.000 title abstract 3
- 229960005370 atorvastatin Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Abstract
Ovaj pronalazak se odnosi na farmaceutske kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli i antihipertenzivnih agenasa. Ovaj pronalazak se, takodje, odnosi na aditive i sinergističke kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli.[This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5727697P | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU2000A true YU2000A (sh) | 2002-12-10 |
Family
ID=22009602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU2000A YU2000A (sh) | 1997-08-29 | 1998-08-11 | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US20020099046A1 (sh) |
| EP (1) | EP1009400B1 (sh) |
| JP (2) | JP2001514223A (sh) |
| KR (3) | KR20010022477A (sh) |
| CN (3) | CN1473566A (sh) |
| AP (1) | AP1191A (sh) |
| AR (1) | AR016399A1 (sh) |
| AT (1) | ATE285767T1 (sh) |
| AU (1) | AU740424B2 (sh) |
| BG (1) | BG64724B1 (sh) |
| BR (1) | BR9811556A (sh) |
| CA (1) | CA2296723A1 (sh) |
| CO (1) | CO4970724A1 (sh) |
| DE (1) | DE69828413T2 (sh) |
| DZ (1) | DZ2595A1 (sh) |
| EA (1) | EA200000012A1 (sh) |
| EG (1) | EG24678A (sh) |
| ES (1) | ES2234134T3 (sh) |
| GT (1) | GT199800126A (sh) |
| HR (1) | HRP980474A2 (sh) |
| HU (1) | HUP0004318A3 (sh) |
| ID (1) | ID24118A (sh) |
| IL (2) | IL133962A0 (sh) |
| IS (1) | IS5341A (sh) |
| MA (1) | MA26536A1 (sh) |
| MY (1) | MY121008A (sh) |
| NO (1) | NO323987B1 (sh) |
| NZ (2) | NZ530630A (sh) |
| OA (1) | OA11291A (sh) |
| PA (1) | PA8457901A1 (sh) |
| PE (1) | PE107099A1 (sh) |
| PL (1) | PL339091A1 (sh) |
| PT (1) | PT1009400E (sh) |
| SA (1) | SA98190603B1 (sh) |
| SK (1) | SK1432000A3 (sh) |
| TN (1) | TNSN98155A1 (sh) |
| TR (1) | TR200000563T2 (sh) |
| UY (1) | UY25155A1 (sh) |
| WO (1) | WO1999011260A1 (sh) |
| YU (1) | YU2000A (sh) |
| ZA (1) | ZA987839B (sh) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40792E1 (en) | 1992-05-19 | 2009-06-23 | Novogen Research Pty Ltd | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| KR20010041916A (ko) * | 1998-03-17 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제 |
| WO2000038721A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| SK2692002A3 (en) | 1999-08-30 | 2002-07-02 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| EP1218017B1 (en) | 1999-09-24 | 2005-11-16 | Vasogen Ireland Limited | Combination of a statin and ex-vivo treated blood for treating atherosclerosis |
| FR2803525B1 (fr) * | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| DK1313714T3 (da) | 2000-07-19 | 2008-12-15 | Novartis Ag | Valsartansalte |
| CA2420844A1 (en) * | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Medicinal compositions for preventing or treating heart failure |
| US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| JP4711600B2 (ja) | 2001-01-26 | 2011-06-29 | シェーリング コーポレイション | シトステロール血症の処置のための置換アゼチジノン化合物の使用 |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| CN1537019A (zh) * | 2001-07-19 | 2004-10-13 | �ź㴫 | 醛固酮受体拮抗剂和HMG CoA还原酶抑制剂的药物组合 |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| US6852737B2 (en) * | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| BR0306643A (pt) | 2002-01-17 | 2004-10-19 | Pharmacia Corp | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical |
| JP2005533796A (ja) * | 2002-06-20 | 2005-11-10 | ザ・ガバナーズ・オブ・ザ・ユニバーシティ・オブ・アルバータ | 心臓保護薬または血行動態薬との併用におけるジクロロ酢酸塩 |
| AU2003248746B2 (en) * | 2002-06-27 | 2009-01-08 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
| CA2492084A1 (en) * | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydobromide |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US8734850B2 (en) * | 2003-11-25 | 2014-05-27 | Flamel Technologies | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
| US7750036B2 (en) * | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| KR20050092519A (ko) * | 2004-03-16 | 2005-09-22 | 화이자 인코포레이티드 | 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합 |
| US20070191438A1 (en) * | 2004-04-06 | 2007-08-16 | Rohrer Susan P | Methods for the treatment of hypertension |
| JP4880591B2 (ja) | 2004-06-04 | 2012-02-22 | テバ ファーマシューティカル インダストリーズ リミティド | イルベサルタンを含む医薬組成物 |
| DE602005020462D1 (de) | 2004-08-25 | 2010-05-20 | Essentialis Inc | Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen |
| ZA200706702B (en) * | 2005-02-17 | 2008-11-26 | Chiesi Farma Spa | Therapeutic combinations of manidi pine and a statin |
| WO2007111027A1 (ja) | 2006-03-29 | 2007-10-04 | Kowa Co., Ltd. | トリグリセリド低下剤及び高インスリン血症改善剤 |
| CA2664893C (en) * | 2006-10-30 | 2015-01-27 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| CN102065847A (zh) | 2008-04-29 | 2011-05-18 | 韩诺生物制约株式会社 | 含有血管紧张素-ⅱ受体阻断剂的药物制剂 |
| CZ301299B6 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| NZ594738A (en) * | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| RU2481124C1 (ru) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения |
| CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
| KR20140028971A (ko) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| US20160045497A1 (en) * | 2013-03-12 | 2016-02-18 | Lg Life Sciences Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
| CN104173420A (zh) * | 2013-05-20 | 2014-12-03 | 广州诺氏刘生物科技有限公司 | 一种治疗急性肾衰竭的药物 |
| EP4349330A3 (en) | 2014-10-23 | 2024-07-31 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the pgi2 receptor |
| CN108156807A (zh) * | 2015-06-30 | 2018-06-12 | 韩美药品株式会社 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
| FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| US20200315233A1 (en) * | 2016-06-02 | 2020-10-08 | Ana Pharmaceuticals, Inc. | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| PT3573620T (pt) | 2017-01-25 | 2023-03-20 | The George Inst For Global Health | Composições para o tratamento da hipertensão |
| KR20220119169A (ko) | 2017-03-01 | 2022-08-26 | 아레나 파마슈티칼스, 인크. | Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법 |
| JP7519909B2 (ja) | 2018-05-16 | 2024-07-22 | アレーナ ファーマシューティカルズ，インク． | Ｐｇｉ２－受容体アゴニストを含む組成物、およびその調製のためのプロセス |
| CN112770746A (zh) * | 2018-07-26 | 2021-05-07 | 乔治全球健康研究院 | 用于治疗高血压的组合物 |
| CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| IL118778A (en) * | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
| CN1679953A (zh) * | 1995-11-02 | 2005-10-12 | 沃尼尔·朗伯公司 | 用于调节脂浓度的联合用药 |
-
1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 CA CA002296723A patent/CA2296723A1/en not_active Abandoned
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/en not_active Expired - Lifetime
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/en not_active Ceased
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/xx active
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
-
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
-
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
-
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
-
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU2000A (sh) | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens | |
| MY123993A (en) | Therapeutic combinations | |
| CA2296726A1 (en) | Combination therapy | |
| AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
| EA200300155A1 (ru) | Терапевтическая комбинация ингибитора сетр и аторвастатина | |
| IL132853A0 (en) | Combination therapy for modulating the human sexual response | |
| ES2175437T3 (es) | Composicion de enalapril y losartan. | |
| WO1998042650A3 (en) | Leukotriene antagonists useful for treating cystic fibrosis | |
| ECSP982647A (es) | Terapia de combinacion | |
| ECSP982645A (es) | Terapia de combinacion | |
| ECSP982646A (es) | Combinaciones terapeuticas | |
| AU6920398A (en) | Medicament for preventive and therapeutic treatment of inflammatory diseas es |